Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 289-296

  Motzer, Robert J ^a   Bacik, Jennifer ^a   Murphy, Barbara A ^a   Russo, Paul ^a   Mazumdar, Madhu ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CALCIUM; HEMOGLOBIN; ISOTRETINOIN; LACTATE DEHYDROGENASE; VINBLASTINE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 0036138580     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.289     Document Type: Article

References (36)

1. Renal cell carcinoma
2. Kidney cancer
3. Immunotherapy in renal cell carcinoma
4. Renal cell carcinoma: Management of advanced disease
5. Systemic therapy for renal cell carcinoma
6. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
7. Interferon-alpha and survival inmetastatic renal carcinoma: Early results of a randomised controlled trial
8. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
9. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
10. Cytoreduction nephrectomy in metastatic renal cancer: The results of the Southwest Oncology Group trial 8949
11. Tumor nephrectomy plus interferon alpha is superior to interferon alpha alone in metastatic renal cell carcinoma
12. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up
13. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma
14. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro
15. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
16. Reporting results of cancer treatment
17. Nonparametric estimation from incomplete observations
18. Evaluation of survival data and two new rank order statistics arising in its consideration
19. Categorizing a prognostic variable: Review of methods, codes for easy implementation and application to decision-making about cancer treatments
20. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model
21. A bootstrap resampling procedure for model building: Application to the Cox regression model
22. Renal-cell carcinoma
23. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study
24. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases
25. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
26. Randomised study using IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer
27. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alfpha and gamma in patients with advanced renal cell carcinoma
28. A multi-center phase II trial of interleukin-2, interferon-alpha, and 13 cis-retinoic acid in patients with metastatic renal cell carcinoma
29. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma
30. Prognostic factors of adult metastatic renal cell carcinoma: A multivariate analysis
31. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2
32. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis
33. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha
34. Interleukin-2-based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive patients